Earnings calls

Hester Bios concall ledger

Every earnings call for HESTERBIO — management tone, guidance, KPIs and promise tracking, quarter by quarter.

HESTERBIO · 5 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 15 May 2026Call held 15 May 2026

HESTERBIO Q4 FY26 Earnings Call Transcript & Analysis

Standalone Q4 Revenue Growth—+22% YoYStandalone Q4 PAT Growth—+174% YoYStandalone FY26 Revenue Growth—Standalone FY26 PAT Growth—+64% YoYConsolidated Q4 Revenue Growth—+22% YoY

Q4 standalone revenue grew by 22% and PAT increased by 174%.

Read full transcript & analysis

Q2 FY26Published 30 Jan 2026Call held 30 Jan 2026

HESTERBIO Q2 FY26 Earnings Call Transcript & Analysis

Stand-alone Revenue Growth0.12%+12% YoYStand-alone PAT Growth1.4%+140% YoY9M Stand-alone Revenue Growth-0.05%−5% YoY9M Stand-alone Profit Growth0.16%+16% YoYConsolidated Revenue Growth0.22%+22% YoY

Stand-alone Revenue Growth 0.12% (+12% YoY); Stand-alone PAT Growth 1.4% (+140% YoY); 9M Stand-alone Revenue Growth -0.05% (−5% YoY). Stand-alone revenue grew 12% in Q3 FY26, with PAT up 140% YoY.

Read full transcript & analysis

Q1 FY26Published 01 Aug 2025Call held 01 Aug 2025

HESTERBIO Q1 FY26 Earnings Call Transcript & Analysis

Standalone Revenue₹63 cr−14% YoY

Standalone Revenue ₹63 cr (−14% YoY). Consolidated PAT grew over 100% YoY.

Read full transcript & analysis

Q4 FY25Published 09 May 2025Call held 09 May 2025

HESTERBIO Q4 FY25 Earnings Call Transcript & Analysis

Hester Nepal Net Profit₹1.2 crHester Africa Net Loss₹10.2 cr

Hester Nepal Net Profit ₹1 cr; Hester Africa Net Loss ₹10 cr. Standalone profit grew by 17% for FY25 and 30% in Q4.

Read full transcript & analysis

Q3 FY25Published 30 Jan 2025Call held 30 Jan 2025

HESTERBIO Q3 FY25 Earnings Call Transcript & Analysis

Consolidated EBITDA—+12% YoYStandalone PAT—−31% YoY

Consolidated profit grew by 85% for 9 months compared to the previous year.

Read full transcript & analysis